MedTrace Logo

Silymarin Bioavailability Study

NCT06882681 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-03-18

No results posted yet for this study

Summary

This study seeks to evaluate and compare the pharmacokinetics of a novel micellar silymarin formulation with that of a standard silymarin formulation.

Conditions

  • Bioavailability and Pharmacokinetics

Interventions

DIETARY_SUPPLEMENT

LipoMicel Milk Thistle

A maximum single dose of approx. 140 mg silymarin (in soft gel capsule)

DIETARY_SUPPLEMENT

Unformulated Milk Thistle Extract

A maximum single dose of approx. 130 mg silymarin (in hard gel capsules)

Sponsors & Collaborators

  • Isura

    lead OTHER

Principal Investigators

  • Julia Solnier, PhD · Isura

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-12-20
Completion
2025-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06882681 on ClinicalTrials.gov